summary
The case of a patient who developed acute dystonia during treatment with aripiprazole prompted us to review the literature for reports on similar cases. From the literature we conclude that aripiprazole has a favourable profile as far as extrapyramidal side effects are concerned. However, the reports on extrapyramidal side effects in the literature may be incomplete. It is therefore still important that such cases are reported within the framework of post-marketing surveillance.